Product image of Methergin (Methylergometrine Maleate) supplied by GNH India

Methergin

Active Ingredient:
Methylergometrine Maleate
Origin:
EU

Methergin (Methylergometrine Maleate)

Methylergometrine Maleate, the active ingredient in Methergin, is an ergot alkaloid presented as an injectable solution for intramuscular or intravenous use. It is employed to prevent and treat postpartum hemorrhage by promoting uterine contraction in women after delivery.

GNH India supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process.

Manufacturer / TM Owner

Essential Pharma Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methergin is a uterotonic agent used in obstetric care to manage bleeding related to childbirth.

  • Prevention of postpartum hemorrhage: Reduces the risk of excessive bleeding by stimulating uterine contraction immediately after delivery.
  • Treatment of postpartum hemorrhage: Controls active bleeding when uterine atony occurs following birth.
  • Control of uterine bleeding after delivery: Assists in achieving hemostasis during the early postpartum period.

How It Works

  • Methylergometrine Maleate acts as a partial agonist at serotonin 5‑HT2 receptors and alpha‑adrenergic receptors on uterine smooth muscle. This dual receptor activation leads to increased intracellular calcium, causing sustained uterine contraction and reduced uterine blood flow, which helps to control postpartum bleeding.

Side Effects

Methergin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Vomiting: occasional episodes after injection.
  • Hypertension: transient increase in blood pressure.
  • Headache: mild to moderate intensity.
  • Abdominal pain: cramp‑like discomfort.
  • Flushing: temporary reddening of skin.

Serious or Rare Side Effects

  • Coronary artery spasm: chest pain with possible ischemia.
  • Myocardial infarction: rare heart attack events.
  • Severe hypertension: rapid and dangerous rise in blood pressure.
  • Seizures: uncommon neurologic events.
  • Pulmonary edema: fluid accumulation in lungs.
  • Allergic reactions: including anaphylaxis and severe skin rash.

Precautions & Warnings

Before using Methergin, clinicians should consider several safety measures.

  • Assess cardiovascular status: monitor blood pressure and heart rate before and during administration.
  • Evaluate for hypertension: avoid use in patients with uncontrolled high blood pressure.
  • Review drug history: contraindicated with MAO inhibitors and other ergot alkaloids.
  • Monitor for signs of ischemia: watch for chest pain or ECG changes.
  • Use caution in patients with coronary artery disease: consider alternative therapies.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methergin can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

  • MAO inhibitors: risk of severe hypertensive crisis.
  • Other ergot alkaloids (e.g., ergotamine): additive vasoconstriction.
  • Potent CYP3A4 inhibitors: increased plasma levels of methylergometrine.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may require dose adjustment due to blood pressure changes.

  • Serotonergic drugs: potential for serotonin syndrome.
  • Hepatic enzyme inducers: may reduce drug efficacy.
  • Calcium channel blockers: possible additive cardiovascular effects.

Frequently Asked Questions

Methergin is used to prevent and treat postpartum hemorrhage and to control uterine bleeding after delivery. It works by stimulating uterine muscle contraction, helping to reduce excessive bleeding in the immediate postpartum period.

Methylergometrine maleate acts as a partial agonist at serotonin 5‑HT2 receptors and alpha‑adrenergic receptors on uterine smooth muscle. This dual activation increases intracellular calcium, leading to strong uterine contractions that promote hemostasis after childbirth.

The specific dose of Methergin is determined by the prescribing clinician based on the patient's condition, route of administration, and clinical guidelines. Healthcare professionals should follow local protocols and adjust dosing as needed.

Methergin is classified as Pregnancy Category X, indicating it should not be used during pregnancy except for its intended obstetric indication after delivery. It is not recommended for breastfeeding mothers because it may pass into milk and affect the infant.

To order Methergin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Methergin belongs to the ergot alkaloid class, offering a longer duration of uterine contraction compared with oxytocin. Unlike prostaglandin analogues, it has a distinct receptor profile, which can be advantageous in cases where other uterotonics are ineffective, but it also carries a higher risk of vasoconstrictive side effects.

Methergin should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintain the cold chain during transport and keep the product in its original packaging until use to preserve stability.

Methergin is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and rate of infusion are determined by the treating clinician, who follows established obstetric protocols.

Serious risks include severe hypertension, coronary artery spasm, myocardial infarction, pulmonary edema, seizures, and anaphylactic reactions. Patients should be closely monitored for cardiovascular and respiratory symptoms during and after administration.

Methergin is contraindicated in patients with uncontrolled hypertension, known coronary artery disease, a history of ergot toxicity, or those taking monoamine oxidase inhibitors. It should also be avoided in individuals with hypersensitivity to ergot alkaloids.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.